FDA Rejects Loxapine for Approval

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) saying that the new drug application for loxapine inhalation powder (Adasuve, Alexza Pharmaceuticals, Inc) is not ready for approval in its current form.

According to a company news release, the deficiencies are medical device specific and readily addressable. Company officials plan to meet with the FDA as soon as practical in order to gain a "better understanding" of the specific problems and resolve remaining issues in a timely manner.
Source: http://nocache-phx.corporate-ir.net/phoenix.zhtml?c=196151&p=RssLanding&cat=news&id=1691575

In past: Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted to recommend that ADASUVE(TM) (Staccato® loxapine) be approved for use as a single dose in 24 hours when used with the FDA recommended Risk Evaluation and Mitigation Strategy (REMS), for the treatment for agitation in patients with schizophrenia or bipolar mania.
Source: https://psychiatry.forumotion.com/t260-fda-approves-inhaled-antipsychotic-loxapine?highlight=loxapine

For more information: http://www.medscape.com/viewarticle/763367?src=rss&utm_source=twitterfeed&utm_medium=twitter